Appliation of the combination of antiangiogenic agents and EGFR-TKIs in advanced NSCLC treatment
10.3760/cma.j.issn.1673-422X.2017.01.015
- VernacularTitle:抗血管生成药物联合EGFR-TKI在晚期NSCLC治疗中的应用
- Author:
Liyan QU
;
Xiaoyan KANG
;
Xia SONG
- Keywords:
Carcinoma,non-small-cell lung;
Angiogenesis inhibitors;
Epidermal growth factor recep-tor-tyrosine kinase inhibitors
- From:
Journal of International Oncology
2017;44(1):57-59
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)and anti-angio-genic drugs have individually demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Recent studies demonstrate that the combination of anti-EGFR and anti-angiogene-sis can more significantly enhance clinical benefit,and even can remit EGFR-TKIs resistance in the treatment of advanced NSCLC.According to the different kinds of anti-angiogenesis drugs,recent clinical studies mainly include the combination of anti-vascular endothelial growth factor monoclonal antibody bevacizumab plus EGFR-TKIs and multi-targeted receptor anti-angiogenic tyrosine kinase inhibitor plus EGFR-TKIs,and the for-mer results show a more significant improvement in terms of safety and efficacy in the treatment of advanced NSCLC.Therefore,the combination of bevacizumab plus EGFR-TKIs can be used as a new treatment standard in the treatment of some patients with NSCLC.
